The individuals that form the Imagepace management team consist of knowledgeable physicians and staff with scientific and clinical trial experience in the field of IMT as a surrogate cardiovascular endpoint. The management team consists of the following individuals.

Daniel O’Leary, MD, Director – Research and Development

Daniel H. O’Leary is Professor of Radiology at Tufts University School of Medicine and President of Caritas Carney Hospital in Boston, Massachusetts. He received his BA from Harvard College and his MD from Tufts University School of Medicine. He trained at the Massachusetts General Hospital in Boston, is board-certified in Neurology and Radiology, and has subspecialty certification in Neuroradiology.

His research interest has centered on noninvasive imaging of subclinical atherosclerosis. He has authored or co-authored on over 135 research papers in peer-reviewed journals, many of which reflect his pioneering work in the use of ultrasound to measure carotid intima-media thickness (IMT) both to assess cardiovascular risk and track disease progression and regression. Dr. O’Leary has created an Ultrasound Reading Center that has served as the core laboratory for measuring carotid IMT for the great majority of NIH-sponsored multi-center studies that have used this technique during the last two decades.

John Kastelein, MD, Managing/Medical Director (Rotterdam office)

John J.P. Kastelein (1954) is Professor of Medicine and Chairman of the Department of Vascular Medicine at the Academic Medical Centre (AMC) of the University of Amsterdam, where he holds the Strategic Chair of Genetics of Cardiovascular Disease. He received his medical degree in Amsterdam in 1980 where he subsequently received specialty training in internal medicine. Then, he was trained in medical genetics, lipidology, and molecular biology at the University of British Columbia, Vancouver, Canada, under the guidance of Prof. Dr. M.R. Hayden.

Upon his return to the Netherlands, he was awarded a doctorate (Cum Laude) and he founded the Lipid Research Clinic at the AMC in Amsterdam, which is currently serving as a tertiary referral centre for over five thousand patients each year.

In 1997 and 1998, he served a visiting Professorship at the Center for Molecular Medicine and Therapeutics at the University of British Columbia. Since then, he has set up a foundation for the active identification of patients with classical familial hypercholesterolemia in the Netherlands, for which he currently holds a position in the board of directors. He is president of the Dutch Atherosclerosis Society (DAS) as well as the National Scientific Committee on Familial Hypercholesterolemia (EHC). He is a member of the Royal Dutch Society for Medicine & Physics, the Council for Basic Science of the American Heart Association, and the European Atherosclerosis Society. He is also a board member of the International Task Force for CHD Prevention.

Professor Kastelein’s major research interests lie in the molecular basis of hypertriglyceridemia, hypercholesterolemia, and low HDL cholesterol. He has published over 300 research papers in peer reviewed journals, including Nature Genetics, Lancet, New England Journal of Medicine, JAMA, and Circulation, and was awarded an Established Investigatorship of the Dutch Heart Foundation. He also serves on a number of executive and steering committees of lipid-lowering intervention trials, including the IDEAL, TNT, CAPTIVATE, ENHANCE, and torcetrapib imaging and M&M studies. He has directed 20 postdoctoral theses, and currently heads a team of 2 internists, 6 postdoctoral fellows, 17 MD and PhD students, 16 laboratory technicians, 16 trial coordinators, and is Director of the Core Echo Laboratory (CEL) at the AMC.